Literature DB >> 20811322

In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer.

Alexis B Cordero1, Youngjoo Kwon, Xiang Hua, Andrew K Godwin.   

Abstract

Human cancer and response to therapy is better represented in orthotopic animal models. This paper describes the development of an orthotopic mouse model of ovarian cancer, treatment of cancer via oral delivery of drugs, and monitoring of tumor cell behavior in response to drug treatment in real time using in vivo imaging system. In this orthotopic model, ovarian tumor cells expressing luciferase are applied topically by injecting them directly into the mouse bursa where each ovary is enclosed. Upon injection of D-luciferin, a substrate of firefly luciferase, luciferase-expressing cells generate bioluminescence signals. This signal is detected by the in vivo imaging system and allows for a non-invasive means of monitoring tumor growth, distribution, and regression in individual animals. Drug administration via oral gavage allows for a maximum dosing volume of 10 mL/kg body weight to be delivered directly to the stomach and closely resembles delivery of drugs in clinical treatments. Therefore, techniques described here, development of an orthotopic mouse model of ovarian cancer, oral delivery of drugs, and in vivo imaging, are useful for better understanding of human ovarian cancer and treatment and will improve targeting this disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811322      PMCID: PMC2935696          DOI: 10.3791/2125

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  11 in total

Review 1.  Bioluminescence imaging.

Authors:  Ruxana T Sadikot; Timothy S Blackwell
Journal:  Proc Am Thorac Soc       Date:  2005

Review 2.  Animal models of ovarian cancer.

Authors:  Denise C Connolly
Journal:  Cancer Treat Res       Date:  2009

3.  Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events.

Authors:  Steffi Lehmann; Daniel P Stiehl; Michael Honer; Marco Dominietto; Ruth Keist; Ivana Kotevic; Kristin Wollenick; Simon Ametamey; Roland H Wenger; Markus Rudin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-31       Impact factor: 11.205

4.  Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer.

Authors:  Tanya J Shaw; Mary K Senterman; Kerri Dawson; Colleen A Crane; Barbara C Vanderhyden
Journal:  Mol Ther       Date:  2004-12       Impact factor: 11.454

5.  Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents.

Authors:  Denise C Connolly; Harvey H Hensley
Journal:  Curr Protoc Pharmacol       Date:  2009-06-01

Review 6.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

Review 7.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

8.  Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.

Authors:  James Greenaway; Roger Moorehead; Patricia Shaw; Jim Petrik
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 10.  Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.

Authors:  M C Bibby
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

View more
  19 in total

Review 1.  Non-invasive molecular imaging for preclinical cancer therapeutic development.

Authors:  A C O'Farrell; S D Shnyder; G Marston; P L Coletta; J H Gill
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

2.  CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.

Authors:  Tomoe Higuchi; Dallas B Flies; Nicole A Marjon; Gina Mantia-Smaldone; Lukas Ronner; Phyllis A Gimotty; Sarah F Adams
Journal:  Cancer Immunol Res       Date:  2015-07-02       Impact factor: 11.151

3.  An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.

Authors:  L Zhao; G Ji; X Le; Z Luo; C Wang; M Feng; L Xu; Y Zhang; W B Lau; B Lau; Y Yang; L Lei; H Yang; Y Xuan; Y Chen; X Deng; T Yi; S Yao; X Zhao; Y Wei; S Zhou
Journal:  Oncogene       Date:  2017-01-23       Impact factor: 9.867

4.  Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: an in vivo study in orthotopic xenografts of nude mice.

Authors:  Xiaofei Xu; Bushra Ayub; Zhaojian Liu; Vanida Ann Serna; Wenan Qiang; Yugang Liu; Eva Hernando; Sonya Zabludoff; Takeshi Kurita; Beihua Kong; Jian-Jun Wei
Journal:  Mol Cancer Ther       Date:  2014-05-13       Impact factor: 6.261

5.  Induction of protective immunity against Chlamydia muridarum intracervical infection in DBA/1j mice.

Authors:  Lingli Tang; Zhangsheng Yang; Hongbo Zhang; Zhiguang Zhou; Bernard Arulanandam; Joel Baseman; Guangming Zhong
Journal:  Vaccine       Date:  2013-11-01       Impact factor: 3.641

Review 6.  Mouse models of epithelial ovarian cancer for preclinical studies.

Authors:  Sergey Karakashev; Ru-Gang Zhang
Journal:  Zool Res       Date:  2021-03-18

7.  The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling.

Authors:  Silvia Zecchini; Lorenzo Bombardelli; Alessandra Decio; Marco Bianchi; Giovanni Mazzarol; Fabio Sanguineti; Giovanni Aletti; Luigi Maddaluno; Vladimir Berezin; Elisabeth Bock; Chiara Casadio; Giuseppe Viale; Nicoletta Colombo; Raffaella Giavazzi; Ugo Cavallaro
Journal:  EMBO Mol Med       Date:  2011-07-08       Impact factor: 12.137

8.  First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.

Authors:  Oystein Helland; Mihaela Popa; Olav K Vintermyr; Anders Molven; Bjørn Tore Gjertsen; Line Bjørge; Emmet McCormack
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

9.  An orthotopic murine model of human prostate cancer metastasis.

Authors:  Janet Pavese; Irene M Ogden; Raymond C Bergan
Journal:  J Vis Exp       Date:  2013-09-18       Impact factor: 1.355

10.  Effect of soy isoflavones on the growth of human breast tumors: findings from preclinical studies.

Authors:  Youngjoo Kwon
Journal:  Food Sci Nutr       Date:  2014-07-10       Impact factor: 2.863

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.